Improving Stroke Risk Stratification in Atrial Fibrillation
To access this article, please choose from the options below
Funding: None.
Conflict of Interest: Dr Lip has received funding for research, consultancy, and lecturing from different manufacturers of drugs used for the treatment of atrial fibrillation, including AstraZeneca, Bayer, Boehringer Ingelheim, Astellas, Sanofi-Aventis, and Daichii-Sankyo. Dr Halperin has received consulting fees from Astellas Pharma, Bayer HealthCare, Biotronik, Boehringer Ingelheim, Daiichi Sankyo, Johnson & Johnson, and Sanofi-Aventis, and an honorarium from Portola Pharmaceuticals for data safety monitoring activities.
Authorship: All authors had access to the data and played a role in writing this manuscript.
PII: S0002-9343(09)01151-6
doi:10.1016/j.amjmed.2009.12.013
© 2010 Elsevier Inc. All rights reserved.

